Evidence map›Paper›PMID 42258557›Full record

ArticlePLoS neglected tropical diseases2026

Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromycosis: a multicenter retrospective study.

Zhikai Wan, Mengyan Wang, Weiwei Zhang, Yu Zhou, Biao Zhu

Abstract readMulticenter Study
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhikai WanThe Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Mengyan WangThe Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Weiwei ZhangDepartment of Infectious Disease, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yu ZhouDepartment of Infectious Disease, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Biao ZhuThe Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0001-6288-4575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTalaromycosis is an invasive fungal infection that predominantly affects immunocompromised individuals, with a particularly high incidence and mortality rate among HIV-infected patients. The purpose of this study was to develop and validate a novel nomogram model to predict mortality risk in HIV-associated talaromycosis (HTM) patients.

methodThe authors retrospectively analyzed HTM patients from January 2013 to December 2023 at three research centers. The research participants were randomly divided into the training and validation sets at a ratio of 7:3. To determine the crucial variables for establishment of the predictive model, the study sequentially applied univariate logistic regression, lasso regression, stepwise logistic regression. The validation set was used to assess the performance of the established prediction model, with its efficacy evaluated through receiver operating characteristics curve, clinical decision curves, and calibration curves.

resultA total of 431 subjects were enrolled in the study with 55/431 (12.76%) patients dying during hospitalization. Statistical analysis shows that there was no difference between training set and validation set in the baseline demographic and clinical characteristics. Five factors including breathlessness, elevated TB, APRI, CRP and decreased Hb were identified as predictive factors for HTM mortality. A nomogram model was built and the area under the curve (AUC) for the nomogram in predicting death was 0.83 (95% CI: 0.76-0.90) in the training set and 0.81 (95% CI: 0.70-0.93) in the validation set. The H-L test and calibration curves showed a strong alignment between predicted and actual results in both sets. Additionally, the decision curve analysis (DCA) indicated that the model provided significant net benefits for patients experiencing poor outcomes.

conclusionThe nomogram model developed in this study integrating easily accessible clinical indicators and symptoms is effective in predicting in-hospital mortality in patients with HTM, which will greatly assist clinicians in the individual management of HTM patients.

Indexed as

HIV InfectionsHospital MortalityMycosesAdultFemaleHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisNomogramsRetrospective StudiesROC Curve

Identifiers

PMID42258557
PMCPMC13262935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.